Drugs / BNT162b2s01
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04949490 | Jul 2021 → Apr 2022 | COVID-19 | BioNTech SE | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT162b2s01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04949490 ↗ |
| Modality | Vaccine | “last injection of a BNT162 candidate vaccine in the parent BNT162-01 or BNT162-04 trials” NCT04949490 ↗ |